Inovio Pharmaceuticals Investors Alerted to Lawsuit

- The lawsuit alleges that Inovio Pharmaceuticals made false or misleading statements concerning manufacturing deficiencies with its CELLECTRA device. - These alleged manufacturing issues were revealed on August 8, 2024, causing a delay in the submission of the Biologics License Application (BLA) for INO-3107, a treatment for recurrent respiratory papillomatosis. - Following the announcement of the BLA submission delay, Inovio's stock price fell 3.1% to close at $8.44 per share on August 9, 2024. - The company's stock dropped again on December 29, 2025, falling 24.45% to $1.73 per share, after disclosing that the FDA had accepted the INO-3107 application for a standard review, not the previously touted accelerated timeline. - The lead plaintiff in a class-action lawsuit is a representative party who makes key decisions about the litigation, including any potential settlements, on behalf of all investors who purchased securities during the class period. - The law firm behind the notice, Rosen Law Firm, has a history of securing large settlements in securities class-action lawsuits, including recovering $438 million for investors in 2019 alone. - Inovio has a history of stock volatility and was the subject of a previous class-action lawsuit in 2020, which alleged misleading claims about the rapid development of a COVID-19 vaccine. - An investor's eligibility to share in any potential recovery is not dependent on serving as the lead plaintiff; they can also choose to remain an absent class member.